This is a recommended evaluation and management algorithm from the Western Trauma
Association (WTA) Algorithms Committee focused on the management of pharmacologic
prophylaxis for venous thromboembolism (VTE) prevention in trauma patients. Because
there are few related published prospective, randomized clinical trials that have
generated class I data on this topic in the trauma population, these recommendations
are based primarily on published prospective and retrospective cohort studies, and
expert opinion of the WTA members. The final algorithm is the result of an iterative
process including an initial internal review and revision by the WTA Algorithm Committee
members, and then final revisions based on input during and after presentation of
the algorithm to the full WTA membership.
Goals
The algorithm (Fig. 1) and accompanying comments represent a safe and sensible approach
to reducing VTE in trauma patients. The aim for this approach was to provide updated
guidelines that apply to most patients, most of the time. We recognize that there
will be multiple factors that may warrant or require deviation from any single recommended
algorithm and that no algorithm can completely replace expert bedside clinical judgment.
We encourage institutions and clinicians to use this algorithm as a general framework
in the approach to trauma patients and to customize and adapt it to better suit the
specifics of that program or location.
Figure 1
The WTA algorithm for VTE prophylaxis after trauma. Circled letters correspond to
sections in the associated article. Algorithm circle-bubbles represent patient criteria;
algorithm square-bubbles represent expert recommendations. CrCl, creatinine clearance;
Hb, hemoglobin; LMWH, enoxaparin; q8h, every 8 hours; q12h, every 12 hours; UFH, unfractionated
heparin.
Burden of Disease
Venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism
(PE), is a potentially preventable complication after trauma. The focus of this algorithm
is on optimizing the delivery of pharmacologic prophylaxis to prevent VTE and minimize
any associated complications. For those trauma patients diagnosed with a DVT or PE,
including distal upper extremity or calf thrombosis, specific treatments are addressed
in other guidelines and will not be covered in this algorithm.
1,2
Without pharmacologic prophylaxis, a 1994 study determined that the DVT rate was 58%
in severely injured trauma patients who undergo serial impedance plethysmography with
lower extremity contrast venography.
3
In a landmark, 1996 New England Journal of Medicine publication 30 mg of subcutaneous
enoxaparin twice daily performed better than 5,000 U of subcutaneous heparin twice
daily at reducing DVT in moderate to severely injured trauma patients (31% vs. 44%,
p = 0.04).
4
The risk of major bleeding was low regardless of therapy, and importantly, the first
dose of pharmacologic prophylaxis was initiated within 36 hours of the injury and
continued through all surgical procedures except spinal fixation when a single preoperative
dose was held.
4
This study established that early, uninterrupted enoxaparin was superior to heparin
at reducing VTE after trauma. In the last decade, a number of reviews and societal
recommendations focused on improving the guidelines to reduce the rate of VTE and
related complications after trauma.
1,2,5–11
Despite this progress, debate persists regarding optimal dosing and timing of enoxaparin,
including when to initiate, hold, and resume it before and after surgery or epidural
placement. Trauma patients frequently receive a delayed, suboptimal dose of enoxaparin,
which is then held for any potential surgical procedure despite substantial evidence
that encourages early, uninterrupted pharmacologic prophylaxis. An updated algorithm
on the appropriate management of VTE prophylaxis is therefore indicated.
ALGORITHM
The following lettered sections correspond to the letters identifying specific sections
of the algorithm shown in Figure 1. In each section, we provide a brief summary of
the important aspects and options that should be considered at that point in the evaluation
and management process.
A
This algorithm is designed for adult trauma patients 18 years and older.
Importantly, although younger children have a significantly lower VTE risk, older
children and adolescents have a VTE risk that approaches their adult counterparts.
12
Guidance for VTE prophylaxis in children can be found in the joint practice management
guideline from the Pediatric Trauma Society and the Eastern Association for the Surgery
of Trauma, which recommends, “pharmacologic prophylaxis be considered for children
older than 15 years old and in younger postpubertal children with Injury Severity
Score (ISS) greater than 25.”
11
B
Assessment of VTE risk will assist in determining which patients require pharmacologic
prophylaxis.
In general, an ISS of 10 or more suggests that pharmacologic prophylaxis should be
initiated as soon as possible, whereas patients with an ISS of less than 10 are at
lower VTE risk and may not require pharmacologic prophylaxis.
13–15
Because ISS is not calculated in real time, the Greenfield Risk Assessment Profile
or the Trauma Embolic Scoring System can assist with calculating VTE risk.
13–15
Patients with spine or pelvic fractures, repair of venous injury, a history of VTE,
or inherited clotting disorders have increased VTE risk and should be considered for
pharmacologic prophylaxis.
2,13,14
Among trauma patients with minor injuries, independent predictors of increased VTE
risk are increased age, obesity, and lower extremity fractures; any combination of
these three characteristics should encourage initiation of pharmacologic prophylaxis.
13
C
Patients with minor trauma may not require pharmacologic prophylaxis.
Given the related pain with injection, potential for hematoma at the injection site,
cost for the medication, and nursing costs for administration, avoiding pharmacologic
prophylaxis may be indicated for select low-risk patients after minor trauma. The
Trauma Embolic Scoring System can be used to assess VTE risk, as patients with a low
score require no pharmacologic prophylaxis because of their low VTE rate.
13
Ambulatory patients with minor injuries and short hospital stays may not require pharmacologic
prophylaxis. Trauma patients capable of ambulation but confined to bed because of
intoxication, restraints, or other reasons should receive pharmacologic prophylaxis.
In general, trauma patients who require hospital admission for more than 24 hours
require pharmacologic prophylaxis, whereas those hospitalized for less than 24 hours
do not. For the patients who do not receive pharmacologic prophylaxis, mechanical
prophylaxis and/or aspirin are low cost and low morbidity options, although their
benefit is uncertain given the low VTE rate.
13–16
D
Appropriate delays in pharmacologic prophylaxis may occur for those patients with
an active bleed, coagulopathy, hemodynamic instability, solid organ injury, traumatic
brain injury (TBI), or spinal trauma.
Quantifying the risk and benefit of initiating pharmacologic prophylaxis for each
patient is a challenge that is best determined by the trauma team at bedside. Detailing
every indication where a delay may be indicated is outside the scope of these guidelines;
several are described below. However, it is important to note that the guidance in
both the literature and clinical practice supports very short delays to the initiation
of pharmacologic prophylaxis, even among these cohorts.
Active Bleeding, Coagulopathy, or Hemodynamic Instability
Control of active bleeding is necessary before starting pharmacologic prophylaxis.
In the presence of hemodynamic instability, a hemoglobin drop of greater than 2 g/dL
in under 12 hours or ongoing blood transfusion is an appropriate indication to delay
the initiation of pharmacologic prophylaxis.
2,4
Systemic coagulopathy was previously proposed as a reason to delay pharmacologic prophylaxis
with one study holding pharmacologic prophylaxis for an elevated prothrombin time
of more than 3 seconds above control or a platelet count of less than 50,000 per cubic
millimeter.
4
More recent studies indicate that prothrombin time and platelet count are not as reliable
at predicting systemic coagulopathy as viscoelastic hemostatic assays, which may demonstrate
hypocoagulability and hypercoagulability after trauma.
2,17–19
The hypocoagulability due to trauma largely resolves within 24 hours, after which
hypercoagulability becomes prevalent. In this setting, pharmacologic prophylaxis may
be considered after the initial resuscitation is complete.
17,20
Deferring the initiation of pharmacologic prophylaxis during trauma-induced coagulopathy
is associated with an increased VTE rate such that the initiation of pharmacologic
prophylaxis is encouraged if the hypocoagulable state is expected to resolve and there
are no signs of ongoing bleeding.
17
Solid Organ Injury
Delays occur in the initiation of pharmacologic prophylaxis for patients with solid
organ injury. Several studies indicate that patients with solid organ injury who received
early pharmacologic prophylaxis had lower DVT and PE rates without increased risk
of failure of nonoperative management, bleeding complications, or mortality; these
risks did not increase when pharmacologic prophylaxis was started within 24 hours
compared with within 48 hours.
20–23
Early pharmacologic prophylaxis within 12 to 24 hours appeared to be safe across moderate
American Association for the Surgery of Trauma injury grade and type of solid organ
injury (liver, spleen, and/or kidney), without an increased risk of bleeding that
necessitated intervention or blood transfusion.
21
Although those with grade IV and V injuries should be approached with caution, pharmacologic
prophylaxis may be initiated within 24 hours for most patients with solid organ injury.
21–23
Traumatic Brain Injury
Concern for progression of TBI is a common reason for the delay in initiation of pharmacologic
prophylaxis. This delay is dependent on the type of TBI; those with “cerebral contusion,
localized petechial hemorrhages, or diffuse axonal damage” may safely receive pharmacologic
prophylaxis without delay.
4
When pharmacologic prophylaxis is appropriately delayed, the follow-up computed tomography
(CT) after TBI diagnosis is an important indicator for when to initiate pharmacologic
prophylaxis.
24
For patients with TBI progression on the follow-up CT, exposure to pharmacologic prophylaxis
is a predictor for further progression, and it should be held until a follow-up CT
demonstrates no progression.
24
In contrast, if the follow-up CT demonstrates no TBI progression, then pharmacologic
prophylaxis should be initiated.
24
Importantly, progression of TBI occurs in about 10% of patients with a stable follow-up
CT, regardless of whether pharmacologic prophylaxis is provided or not.
24
Those trauma centers that provide pharmacologic prophylaxis within 24 hours after
TBI have significantly lower rates of VTE with no difference in rates of late neurosurgical
intervention.
23,25–30
Even in the setting of combat related penetrating TBI, initiating pharmacologic prophylaxis
24 hours after injury for those patients with a stable CT was safe, with similar progression
rates regardless of pharmacologic prophylaxis.
29
The majority of TBI patients with a stable CT may be initiated on enoxaparin within
24 hours, and nearly all TBI patients should receive pharmacologic prophylaxis within
72 hours of the time of injury.
23,28,31
Spinal Trauma
In the absence of pharmacologic prophylaxis, patients who undergo spine surgery or
those with spine trauma, fracture, or cord injury have a high incidence of VTE,
2
and delays longer than 72 hours lead to a substantial increase in the VTE rate.
32
Pharmacologic prophylaxis must be initiated as soon as possible after spine surgery
or any spine injury.
32,33
Regimens that provide pharmacologic prophylaxis preoperatively
34
or immediately after operative fixation are considered safe.
4,34
When a departmental protocol was implemented that required pharmacologic prophylaxis
preoperatively or the same day of spine surgery, the VTE rate decreased and the rate
of spinal hematoma was unchanged.
34
Similarly, pharmacologic prophylaxis initiated within 48 hours of operative fixation
of traumatic spine fractures did not increase the risk of bleeding, progression of
neurological injury, or postoperative complications including spinal hematoma.
23,33
E
Mechanical prophylaxis for moderate to high VTE risk patients is encouraged regardless
of concurrent pharmacologic prophylaxis.
For patients who are not started immediately on pharmacologic prophylaxis, mechanical
prophylaxis with intermittent pneumatic compression and mobilization, when possible,
should be encouraged. Intermittent pneumatic compression lowers the DVT incidence
if no pharmacologic prophylaxis is initiated and therefore is recommended for patients
with a contraindication to pharmacologic prophylaxis.
2,35,36
In contrast, the addition of intermittent pneumatic compression in critically ill
patients who received pharmacologic prophylaxis did not lead to a reduction in the
DVT rate, although the study had a low DVT rate and only 8% of the population were
trauma patients.
16
Combining mechanical prophylaxis with pharmacologic prophylaxis is therefore encouraged
for moderate to high VTE risk patients in part because those who received the combination
had a lower incidence of symptomatic PE.
35
Compression stockings do not appear to reduce the VTE rate in the presence of pharmacologic
prophylaxis,
16
but thigh high compression stockings may provide a benefit to those trauma patients
who cannot be started on pharmacologic prophylaxis.
2
Mobility is also an important component for VTE prevention, as early mobility leads
to a reduction in VTE.
37
A mobility protocol is safe in trauma patients and may reduce patient deconditioning
besides decreasing the rate of VTE.
37
Prolonged maintenance of spinal precautions is associated with an increased DVT rate
and should be avoided to allow early mobility.
38
F
Weekly venous compression duplex should be considered in patients at high VTE risk
who cannot be started or maintained on pharmacologic prophylaxis.
Although debate persists, routine surveillance with venous compression duplex is not
indicated or feasible for all trauma patients.
2
Routine surveillance duplex after trauma does not decrease the risk of PE or fatal
PE, and false-positive results lead to unnecessary therapeutic anticoagulation.
2
In trauma patients at low VTE risk, the high cost and low yield of acute, clinically
relevant findings suggest that the practice may be avoided. Some institutions advocate
for routine surveillance in low-risk trauma patients to identify both acute and preexisting
DVT, which may help identify and treat the related complications such as venous insufficiency,
venous stasis ulcers, or pain with ambulation.
39
For trauma patients at high VTE risk, routine surveillance duplex is associated with
a reduced PE rate.
39
The Greenfield Risk Assessment Profile can identify which trauma patients may benefit
from routine surveillance.
14,39
Weekly duplex scanning may be particularly beneficial in high VTE risk patients who
cannot be started or maintained on pharmacologic prophylaxis. Whatever the institutional
guidelines, identification of DVT should not be a hospital-reported outcome. Institutions
that routinely screen all trauma patients have higher rates of DVT, and those centers
with comprehensive quality improvement efforts that do not routinely screen will also
have higher DVT rates because of a lower threshold for ordering a venous compression
duplex.
G
Pharmacologic prophylaxis must be initiated as soon as possible and for most trauma
patients may be initiated within 24 hours.
When high VTE risk trauma patients who receive enoxaparin within 24 hours of admission
are compared with those who receive only mechanical prophylaxis, minor and major bleeding
events do not differ.
40
As detailed in section E, appropriate delays may occur in the initiation of pharmacologic
prophylaxis because of active bleeding, coagulopathy, hemodynamic instability, solid
organ injury, TBI, or spinal trauma. In most cases, pharmacologic prophylaxis may
be started in less than 24 hours, and in almost every case, pharmacologic prophylaxis
may be started in less than 72 hours.
Pharmacologic prophylaxis is often held because of pending surgery despite the evidence
that it may be initiated before most surgical procedures.
4,41–43
Trauma patients who require an operation are unique in that their first operation
may occur within minutes of arrival or days into the hospitalization. Increasingly,
pharmacologic prophylaxis is delayed or skipped for pending surgery, which leads to
an increased VTE rate.
40
Preoperative dosing of pharmacologic prophylaxis is not unique to trauma. In other
patient populations at high risk for VTE, the use of preoperative pharmacologic prophylaxis
decreased the DVT rate without increasing the complication rate.
41,42
Guidelines for perioperative care in gynecologic/oncology recommend, “Prophylaxis
should be initiated pre-operatively and continued post-operatively.”
44
Patients who underwent elective hip surgery who received low molecular weight heparin
approximately 6 hours before surgery had a lower rate of proximal DVT without increasing
major, minor, or trivial bleeding rates.
43
This benefit was not observed when low molecular weight heparin was provided 12 hours
or more preoperatively.
43
We believe that the common and somewhat reflexive process of withholding pharmacologic
prophylaxis for 12 to 24 hours before planned surgical procedures is almost always
unnecessary and will result in an increased VTE risk without an accompanying decrease
in the risk of bleeding events.
H
After deciding to start pharmacologic prophylaxis, the specific anticoagulant and
initial dose should be determined for each patient. Enoxaparin is the recommended
choice for most trauma patients with higher doses now considered the standard of care.
The preferred agent for pharmacologic prophylaxis is the low molecular weight heparin
enoxaparin because of its increased bioavailability, longer plasma-half life, and
more predictable pharmacokinetics and pharmacodynamics compared with unfractionated
heparin.
4,45
Enoxaparin interacts less with platelets, which may reduce bleeding complications
compared with unfractionated heparin; has a lower incidence of heparin-induced thrombocytopenia
(HIT); and does not have the associated osteoporosis observed with heparin treatment.
46
When choosing the initial dose, 40 mg of enoxaparin twice daily should be considered
the standard for most trauma patients, as 30 mg twice daily frequently results in
inadequate pharmacologic prophylaxis.
47–55
Therefore, patients 18 to 65 years with weight of more than 50 kg and a creatinine
clearance of more than 60 mg/dL should be started on 40 mg of enoxaparin twice daily,
as this dose is safe and reduces the VTE rate.
47–55
Patients who are older than 65 years, weigh less than 50 kg, or who have a creatinine
clearance of 30 to 60 mg/dL should continue to receive initial dosing at 30 mg of
enoxaparin twice daily.
The initial enoxaparin dose for trauma patients with a normal creatine clearance may
also be based on weight. Options include 0.5 mg/kg twice daily,
51,52
0.6 mg/kg twice daily,
53
or 30 mg for 50 to 60 kg patients, 40 mg for 61 to 99 kg patients, and 50 mg for patients
greater than 100 kg.
54
Patients who are initiated on higher doses of enoxaparin based upon weight should
be monitored by anti-Xa levels because of the fluctuations in creatinine clearance
after trauma that might lead to changes in the enoxaparin dose.
50
Although enoxaparin is preferable to heparin for pharmacologic prophylaxis, some institutions
continue to dose unfractionated heparin at 5,000 U three times daily based in part
on a randomized trial that suggested that this regimen might be noninferior and cost-effective
compared with 30 mg of enoxaparin twice daily.
56
This practice should be reconsidered as the trial was underpowered because of an assumed
DVT rate of 44% for unfractionated heparin versus 31% for enoxaparin, and a 10% noninferiority
margin for the power calculation. The actual difference in the VTE rate was 3.1%,
which favored enoxaparin without reaching significance (unfractionated heparin, 8.2%
vs. enoxaparin, 5.1%; p = 0.2).
45,56
In addition, the study was not powered to detect a difference in the rate of PE or
HIT, both of which impact the complication rate and health care costs.
45,57
More recently, 30 mg of enoxaparin twice daily was established as superior to 5000
U of unfractionated heparin three times daily at the prevention of VTE and PE.
45
Unfractionated Heparin for Renal Failure
Quantifying the risk and benefit of the type and initial dose of pharmacologic prophylaxis
for each patient is a challenge best determined by the trauma team at bedside. As
noted, 40 mg of enoxaparin twice daily is the recommended initial pharmacologic prophylaxis
for most trauma patients. Detailing every indication where an alternative therapeutic
or dose may be indicated is outside the scope of these guidelines; several are described
below.
In the presence of end-stage renal disease or a creatinine clearance of <30 mg/dL,
subcutaneous unfractionated heparin at 5000 U every 8 hours may be initiated.
2
Because enoxaparin is excreted by the kidneys, its administration to patients with
renal failure may lead to increased bleeding complications and should be avoided.
2
Enoxaparin has not been Food and Drug Administration approved for use in dialysis
patients. Providing lower enoxaparin doses in the setting of a creatinine clearance
of <30 mg/dL while closely monitoring anti-Xa levels may be possible in the future,
but additional research is necessary before this recommendation can be made. In most
other settings, enoxaparin is preferable to unfractionated heparin, as enoxaparin
leads to lower VTE rates without increased bleeding complications.
4,45
Brain and Spine Trauma
For TBI patients, enoxaparin is associated with less VTE and higher survival than
unfractionated heparin with no difference in the progression of brain lesions, regardless
if the dose was delivered in less than 24 hours after admission, between 24 to 48
hours, or after 48 hours.
26
Similarly, those patients with spine trauma should preferentially receive early enoxaparin.
32,33
Patients with brain and spine trauma should be initiated on 30 mg of enoxaparin twice
daily and considered for dose adjustment by anti-Xa level.
4,47
Pregnant Patients
Pregnant patients require specific dose recommendations for pharmacologic prophylaxis
after trauma because of the progressive hypercoagulability,
58
as well as the increase in renal clearance and weight changes that occur over the
course of pregnancy.
59
These variables generally require higher enoxaparin doses with more frequent dosing.
Neither unfractionated heparin nor enoxaparin crosses the placenta, and both are considered
safe to use in pregnancy.
58–60
As such, during an admission for trauma, pregnant patients should receive 30 mg of
enoxaparin twice daily titrated by anti-Xa levels targeting a peak range of 0.2 to
0.4 IU/mL or a trough range of 0.1 to 0.2 IU/mL. For pregnant patients who weigh more
than 90 kg, initiating 40 mg of enoxaparin twice daily is recommended with similar
anti-Xa level titration.
58–60
Isolated Orthopedic Injuries and Direct Oral Anticoagulants
Pharmacologic prophylaxis with direct oral anticoagulants (DOACs) or aspirin should
not be a primary choice for pharmacologic prophylaxis for most trauma patients because
of the lack of related clinical trials. The use of DOACs or aspirin may be considered
in the setting of isolated orthopedic injuries, but only if the patient declines injection
with enoxaparin or unfractionated heparin.
5,61–66
Two DOACs are approved for pharmacologic prophylaxis after elective orthopedic surgery,
10 mg of rivaroxaban once daily, and 2.5 mg of apixaban twice daily, both which are
direct oral factor Xa inhibitors. Most orthopedic trials that compare rivaroxaban
or apixaban to enoxaparin demonstrate that DOACs have equal to better VTE rates with
similar to higher bleeding rates.
62–64,66–68
In contrast, other analyses conclude that enoxaparin has a lower VTE rate
69
and a lower bleeding rate.
70
Because only retrospective analyses have examined the use of DOACs for pharmacologic
prophylaxis after trauma, randomized controlled trials are necessary before DOACs
becoming a primary agent for trauma patients.
66,71,72
The use of low dose aspirin may also be considered for pharmacologic prophylaxis in
trauma patients with isolated orthopedic injuries who decline injection.
2,5,69,73
For those trauma patients started on a DOAC for pharmacologic prophylaxis, aspirin
may replace the DOAC after 5 days with similar prevention of VTE.
74
I
Many trauma patients require dose adjustment after initiating enoxaparin.
Because of the variations in renal clearance, weight, bioavailability, and coagulation
cascade, monitoring enoxaparin by anti-Xa levels is necessary. In one series, 84%
of trauma patients required doses of 40 mg or more, and 18% required doses of 50 mg
or more.
47
Adjusting enoxaparin by anti-Xa peak or trough levels appears to lower the VTE rate
without increasing bleeding complications in moderate to severely injured patients,
trauma patients who require ICU admission, burn injuries, and surgical oncology patients.
47–49,75
Although some debate exists on the appropriate target for anti-Xa levels, consensus
suggests targeting 0.2 to 0.4 IU/mL for peak levels or 0.1 to 0.2 IU/mL for trough
levels.
47–50,55,75,76
Anti-Xa monitoring should also be considered for those patients who receive weight-based
enoxaparin.
50,53,76
Although thromboelastography (TEG) has not been validated for monitoring pharmacologic
prophylaxis, TEG with platelet mapping may assist with monitoring platelet inhibition.
A randomized trial that used TEG as an adjunct to identify inadequate enoxaparin doses
did not observe lower rates of VTE with the TEG-guided enoxaparin dosing.
77
In contrast, TEG with platelet mapping may help determine if a hypercoagulability
is due to platelet function, which encourages the addition of aspirin to the pharmacologic
prophylaxis regimen.
78
If aspirin is added, the initial recommended dose is 81 mg daily with the possibility
of increasing the dose to 325 mg daily depending on subsequent TEG with platelet mapping
results.
18,19
J
The continuous, uninterrupted dosing of pharmacologic prophylaxis should be the standard
for most trauma patients throughout their hospital stay.
Although the safety and benefit of uninterrupted pharmacologic prophylaxis were established
decades ago, more than half of trauma patients encounter interruptions.
79,80
A direct correlation is observed between the number of missed doses and DVT risk such
that patients who miss two to four doses have 8.5 times higher DVT risk compared with
those with no missed doses.
80
For TBI patients who are started on pharmacologic prophylaxis, interrupted dosing
causes an approximately 600% increase in the VTE rate.
81
The following are common reasons for missed pharmacologic prophylaxis: pending invasive
procedure (41.6%), none (27.1%), patient was absent from the room (11.7%), concern
for bleeding (12.1%), epidural catheter removal (5.9%), and physician/nursing error
(1.6%).
80
When holding pharmacologic prophylaxis, the rate of bleeding with pharmacologic prophylaxis
is no different than without it.
40
If nonfatal VTE events are compared with nonfatal bleeding complications, the risk/benefit
ratio favors continuing pharmacologic prophylaxis.
82
Every effort should focus on continuing pharmacologic prophylaxis without interruption.
The appropriate indications for holding or altering pharmacologic prophylaxis include
acute thrombus, craniotomy, spinal surgery, epidural placement, or HIT, and these
are expanded upon below.
Acute Thrombus
Although routine VTE surveillance is not indicated for all trauma patients,
2
weekly duplex scanning may be warranted in those at high VTE risk.
39
Selective venous compression duplex should be performed promptly for symptomatic evidence
of DVT such as unexpected leg swelling or pain.
6
For those trauma patients with significant injuries and gaps in pharmacologic prophylaxis,
weekly venous compression duplex may be considered.
39
If a DVT or PE is identified, then therapeutic anticoagulation is necessary per current
guidelines, and if it is contraindicated, then an inferior vena cava (IVC) filter
should be considered as detailed in section K.
1
Pending Surgery
As discussed in section G, routinely holding pharmacologic prophylaxis because of
pending surgery is only indicated, with few exceptions, for brain or spine surgery.
4
Given the delays and cancellations of cases that may occur during trauma patient care,
holding pharmacologic prophylaxis preoperatively can cause days of missed pharmacologic
prophylaxis. Preoperative pharmacologic prophylaxis is safe for trauma patients
2,4
and leads to a lower VTE rate.
43
The preoperative administration of pharmacologic prophylaxis is also encouraged for
surgical patients in other specialties who have a high VTE risk and leads to a lower
DVT rate without increasing the complication rate.
4,41–43
The lower VTE rate is lost if pharmacologic prophylaxis is provided more than 12 hours
preoperatively.
43
Epidural Catheter
Epidural catheters reduce morbidity and mortality in trauma patients sustaining chest
injuries and are often a component of multimodal pain strategies. Patients who require
an epidural catheter increasingly have interruptions in pharmacologic prophylaxis
83
such that epidural catheter placement is now associated with an increased VTE rate
84,85
whereas previously this was not the case.
86
Regional Anesthesia Guidelines recommend a 12-hour interval between enoxaparin dose
and epidural placement/removal followed by a 4-hour to 12-hour interval before resumption.
9,10
If enoxaparin is scheduled at 10 am and 10 pm, the morning dose may be held for 10
AM epidural catheter placement/removal to allow for the necessary 12-hour interval
without pharmacological prophylaxis. At 10 PM, the scheduled enoxaparin dosing may
resume, so only one dose is missed. If higher doses of enoxaparin are required for
pharmacologic prophylaxis, Regional Anesthesia Guidelines recommend a 24-hour interval
for therapeutic enoxaparin before epidural catheter placement/removal followed by
a 4-hour to 12-hour interval before resumption,
9,10
indicating that, at most, two doses of enoxaparin should be missed for any enoxaparin
therapy. Anti-Xa–guided enoxaparin doses are encouraged with limited interruption
to reverse the higher VTE rate associated with epidural use.
84,85
For unfractionated heparin, a 4 to 6-hour interval is recommended before epidural
placement/removal followed by a 1-hour interval before unfractionated heparin is resumed,
which allows for uninterrupted dosing.
Heparin-Induced Thrombocytopenia
Selective platelet monitoring should be considered for those trauma patients who receive
pharmacologic prophylaxis because of the risk of heparin-induced thrombocytopenia
(HIT). Platelet monitoring is recommended for patients who are considered high risk
for HIT approximately every 3 days from day 4 to day 14 or until pharmacologic prophylaxis
is stopped.
7
Trauma patients who are exposed only to enoxaparin may be considered low risk for
HIT and may not require routine platelet monitoring, as the rate of clinical HIT was
2.7% with prophylactic heparin compared with 0% with prophylactic enoxaparin.
7,87
The clinical diagnosis of HIT may be predicted by assigning scores that include thrombocytopenia,
timing, thrombosis, and alternative causes.
7,88,89
Once diagnosed, the heparin anticoagulants must be replaced with nonheparin anticoagulants,
such as the direct thrombin inhibitor argatroban, which can create challenges for
trauma patients suspicious for HIT because of the irreversible nature of these anticoagulants
and the difficulties with dosing and maintaining their therapeutic levels.
7,88,89
K
Inferior vena cava filters may be considered in the setting of proximal DVT or PE
when there is a contraindication to appropriate therapeutic anticoagulation.
The use of IVC filters is variable among trauma centers although their placement is
decreasing without a documented change in PE rates, so prophylactic placement is not
recommended.
90
In a randomized controlled trial of high VTE risk trauma patients who were unable
to receive pharmacologic prophylaxis during the first 72 hours of admission, a prophylactic
IVC filter did not lower the incidence of PE or mortality, which established the lack
of utility of early prophylactic placement of an IVC filter in this population.
91
The placement of an IVC filter does not impact mortality regardless of whether a DVT
is present or absent.
92,93
While consensus guidelines provide conflicting recommendations and most studies have
been observational, among patients diagnosed with an acute proximal DVT or PE who
cannot receive adequate therapeutic anticoagulation, an IVC filter should be considered
to reduce the rate of recurrent PE without altering the mortality rate.
94
L
Trauma patients with TBI, orthopedic or spine injuries, and those who undergo major
surgery are at particular VTE risk and should be considered for postdischarge pharmacologic
prophylaxis.
Pharmacologic prophylaxis after discharge for high VTE risk trauma patients is supported
by evidence that demonstrates the practice is efficacious, safe, and cost-effective
and may be considered for patients with TBI, orthopedic or spine injuries, and those
who undergo major surgery.
2,95–98
The highest VTE risk occurs during the first 3 months after injury with approximately
1 year required until the VTE rate returns to that of the general population.
95,97
Venous thromboembolism–related readmissions account for 1.2% of 1-year trauma readmissions
at a cost of US $250 million annually.
99
Postdischarge pharmacologic prophylaxis with enoxaparin is efficacious, associated
with a low rate of clinically relevant bleeding complications, and is cost-effective
in patients at high VTE risk.
2,96
The introduction of postdischarge pharmacologic prophylaxis following abdominal or
pelvic surgery for malignancy or inflammatory bowel disease was associated with a
decrease in VTE events.
98
Because the optimal postdischarge dose and duration of enoxaparin after trauma are
not well studied, doses more than 30 mg twice daily should be avoided, and the duration
of pharmacologic prophylaxis may be considered for up to 4 weeks after the date of
admission.
2
For those who undergo major orthopedic surgery, pharmacologic prophylaxis may be extended
up to 35 days from the date of surgery.
5
Aspirin may be initiated for postdischarge pharmacologic prophylaxis for high VTE
risk trauma patients, as it has been shown to be as effective as enoxaparin with less
bleeding complications and better postdischarge adherence, and is not limited by the
constraints of insurance oversight.
98,100
Direct oral anticoagulants may also be considered for postdischarge pharmacologic
prophylaxis after isolated orthopedic injury.
74
SUMMARY AND CONCLUSIONS
This algorithm was designed to provide comprehensive and clear guidance aimed at reducing
the VTE rate after trauma. Although there are multiple factors that will lead to deviations
from the presented algorithm, most trauma patients should be initiated on early and
higher doses of enoxaparin that often should be adjusted by anti-Xa levels. For most
trauma patients, pharmacologic prophylaxis should continue uninterrupted throughout
the hospital stay and at times after discharge. Avoiding preventable and non–evidence-based
delays to the initiation and missed doses of pharmacologic prophylaxis should be a
best-practice focus of all trauma centers, and it has clearly been associated with
decreased rates of VTE events.